Sonnet biotherapeutics provides fiscal year 2023 third quarter business and earnings update
Combination study of son-1010 with roche's atezolizumab (tecentriq®) has been initiated in australia first son-1010 phase 1 study has been completed and comparison of the human pharmacokinetic data supports targeting of tumor tissue early safety data from the son-080 trial in cipn is expected after the study's data safety monitoring board (dsmb) convenes, prior to calendar year end collaboration with janssen,where in vitro and in vivo efficacy of son-1010, son-1210, and son-1410 are being evaluated in combination with certain janssen cell therapy assets, remains ongoing princeton, nj / accesswire / august 14, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended june 30, 2023 and provided a business update. "sonnet continues to successfully forge ahead with our pipeline development," said pankaj mohan, ph.d.
SONN Ratings Summary
SONN Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission